Tempus AI stock jumps 30% after Morgan Stanley raises revenue outlook on reimbursement clarity.

Tempus AI shares surged nearly 30% this week following Morgan Stanley's optimistic revenue forecast driven by clearer reimbursement pricing for its diagnostic products. CEO Eric Lefkofsky highlighted potential revenue increases of $80-$100 million from xT pricing and $250-$300 million from xF approvals, exceeding prior guidance. The company raised its full-year revenue guidance to about $1.6 billion with 25% growth and expects positive free cash flow by year-end, supported by accelerating data licensing and a promising MRD platform. Despite volatility risks, the market is increasingly bullish on Tempus AI's growth prospects.

Tempus AI shares are trading at USD 79.88 on Pluang as of Sep 17, 2026 23:02 WIB, showing a strong 14.16% gain in one day. The stock's market cap stands at $12.50 billion, reflecting significant investor interest. Buy orders dominate at 84%, indicating bullish sentiment among Pluang users.